A Safety Study of XL019 in Adults With Myelofibrosis

Inclusion Criteria

• •The subject has primary myelofibrosis (PMF), post-polycythemia vera MF, or post-essential thrombocythemia MF and requires therapy, including subjects who have received prior MF-directed therapy and relapsed or subjects with refractory disease; or if newly diagnosed, then with intermediate or high risk according to the Lille scoring system.
• •The subject is unwilling to undergo or is not a candidate for peripheral stem cell/bone marrow transplant.
• •The subject is ≥18 years old.
• •The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
• •The subject has adequate organ function.
• •The subject has the capability of understanding the informed consent document and has signed the informed consent document.
• •Sexually active subjects (male and female) must use medically acceptable methods of contraception during the course of the study.
• •Female subjects of childbearing potential must have a negative pregnancy test at screening.
• •The subject has had no diagnosis of malignancy or evidence of other malignancy for 2 years prior to screening for this study (except non-melanoma skin cancer or in situ carcinoma of the cervix).